A Randomized Open Label Study Comparing Bosentan To Sildenafil First-line Treatment In Pulmonary Arterial Hypertension And Chronic Thromboembolic Pulmonary Hypertension

A randomized open label study comparing first-line treatment with bosentan or sildenafil in Pulmonary Arterial Hypertension (PAH)

European Heart Journal ◽

10.1093/eurheartj/eht308.1063 ◽

2013 ◽

Vol 34 (suppl 1) ◽

pp. 1063-1063

Author(s):

G. Mazzanti ◽

A. Albini ◽

M. Palazzini ◽

E. Monti ◽

C. Bachetti ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Pulmonary Arterial ◽

A Randomized Open Label Study Comparing First-Line Treatment With Bosentan Or Sildenafil In Pulmonary Arterial Hypertension

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4105 ◽

2012 ◽

Cited By ~ 1

Author(s):

Gaia Mazzanti ◽

Massimiliano Palazzini ◽

Enri Leci ◽

Fabio Dardi ◽

Andrea Rinaldi ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Pulmonary Arterial ◽

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

10.1200/jco.2004.22.90140.3658 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3658-3658

Author(s):

T. H. Cartwright ◽

T. Lopez ◽

S. J. Vukelja ◽

C. Encarnacion ◽

K. A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

10.1200/jco.2018.36.15_suppl.tps6090 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS6090-TPS6090 ◽

Cited By ~ 5

Author(s):

Ezra E.W. Cohen ◽

Danny Rischin ◽

David G. Pfister ◽

Jan Baptist Vermorken ◽

Yufan Zhao ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

Annals of Oncology ◽

10.1093/annonc/mdz250.071 ◽

2019 ◽

Vol 30 ◽

pp. v433

Author(s):

C. Marth ◽

C. Vulsteke ◽

M.J. Rubio ◽

V. Makker ◽

E.I. Braicu ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Recurrent Endometrial Cancer ◽

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p171 ◽

2015 ◽

Vol 3 (S2) ◽

Cited By ~ 5

Author(s):

Naiyer Rizvi ◽

Fabrice Barlesi ◽

Julie Brahmer ◽

Enriqueta Felip ◽

Patrick Forde ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Metastatic Nsclc ◽

Platinum Based Chemotherapy ◽

Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.3816/ccc.2005.n.016 ◽

2005 ◽

Vol 5 (1) ◽

pp. 50-56 ◽

Cited By ~ 23

Author(s):

Thomas Cartwright ◽

Timothy Lopez ◽

Svetislava J. Vukelja ◽

Carlos Encarnacion ◽

Kristi A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

10.1200/jco.2004.22.14_suppl.3658 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3658-3658 ◽

Cited By ~ 1

Author(s):

T. H. Cartwright ◽

T. Lopez ◽

S. J. Vukelja ◽

C. Encarnacion ◽

K. A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

10.1200/jco.2005.23.16_suppl.3596 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3596-3596 ◽

Cited By ~ 4

Author(s):

M. Ducreux ◽

A. Adenis ◽

J. Bennouna ◽

T. Conroy ◽

R. Faroux ◽

...

Keyword(s):

Colorectal Cancer ◽

Safety Analysis ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Lung Cancer Targets and Therapy ◽

10.2147/lctt.s142972 ◽

2017 ◽

Vol Volume 8 ◽

pp. 217-229

Author(s):

Wolfgang Schuette ◽

Claus-Peter Schneider ◽

Walburga Engel-Riedel ◽

Christian Schumann ◽

Martin Kohlhaeufl ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽